Wedbush Estimates ImageneBio’s Q4 Earnings (NASDAQ:IMA)

ImageneBio, Inc. (NASDAQ:IMA) – Stock analysts at Wedbush issued their Q4 2025 earnings per share estimates for shares of ImageneBio in a research note issued to investors on Tuesday, November 25th. Wedbush analyst M. Fan forecasts that the company will post earnings per share of ($1.58) for the quarter. Wedbush has a “Underperform” rating on the stock. The consensus estimate for ImageneBio’s current full-year earnings is ($0.91) per share. Wedbush also issued estimates for ImageneBio’s Q1 2026 earnings at ($1.62) EPS, Q2 2026 earnings at ($1.64) EPS, Q3 2026 earnings at ($0.31) EPS, Q4 2026 earnings at ($0.29) EPS, FY2026 earnings at ($2.02) EPS, FY2027 earnings at ($0.74) EPS, FY2028 earnings at ($0.95) EPS and FY2029 earnings at ($1.58) EPS.

Other equities analysts have also issued reports about the stock. Zacks Research lowered shares of ImageneBio from a “strong-buy” rating to a “hold” rating in a report on Monday, September 29th. Leerink Partners initiated coverage on shares of ImageneBio in a research note on Friday, October 24th. They issued an “outperform” rating and a $30.00 price objective on the stock. Wall Street Zen downgraded shares of ImageneBio from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 15th. Leerink Partnrs upgraded ImageneBio to a “strong-buy” rating in a research note on Friday, October 24th. Finally, Weiss Ratings assumed coverage on ImageneBio in a research note on Wednesday, October 22nd. They issued a “sell (e-)” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, ImageneBio presently has an average rating of “Hold” and an average price target of $26.50.

ImageneBio Stock Down 4.7%

IMA opened at $6.91 on Thursday. The stock has a market capitalization of $77.25 million, a price-to-earnings ratio of -0.86 and a beta of 0.42. ImageneBio has a twelve month low of $6.90 and a twelve month high of $23.28. The company has a 50-day simple moving average of $7.98 and a 200 day simple moving average of $12.25.

ImageneBio (NASDAQ:IMA) last released its earnings results on Wednesday, November 12th. The company reported ($2.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.47) by ($1.44).

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of IMA. Citadel Advisors LLC bought a new position in shares of ImageneBio in the 3rd quarter valued at $996,000. Squarepoint Ops LLC bought a new stake in ImageneBio during the 3rd quarter worth $197,000. Jacobs Levy Equity Management Inc. acquired a new position in ImageneBio in the 3rd quarter worth about $144,000. NewEdge Advisors LLC bought a new position in ImageneBio in the third quarter valued at about $106,000. Finally, Bridgeway Capital Management LLC acquired a new stake in shares of ImageneBio during the third quarter valued at about $104,000. 75.00% of the stock is currently owned by institutional investors and hedge funds.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.